Roger Adsett Sells 45,605 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 45,605 shares of the company’s stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $80.90, for a total transaction of $3,689,444.50. Following the completion of the sale, the chief operating officer now directly owns 189,157 shares of the company’s stock, valued at $15,302,801.30. The trade was a 19.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Roger Adsett also recently made the following trade(s):

• On Tuesday, January 14th, Roger Adsett sold 1,457 shares of Insmed stock. The stock was sold at an average price of $68.72, for a total transaction of $100,125.04.
• On Friday, January 10th, Roger Adsett sold 4,902 shares of Insmed stock. The shares were sold at an average price of $63.68, for a total transaction of $312,159.36.
• On Tuesday, January 7th, Roger Adsett sold 2,444 shares of Insmed stock. The shares were sold at an average price of $65.95, for a total transaction of $161,181.80.

Insmed Price Performance

Shares of INSM opened at $79.95 on Monday. The business’s 50-day moving average is $72.88 and its 200-day moving average is $73.09. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The company has a market capitalization of $14.30 billion, a price-to-earnings ratio of -14.41 and a beta of 1.11. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $82.04.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Vestal Point Capital LP grew its holdings in shares of Insmed by 113.3% during the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after acquiring an additional 850,000 shares in the last quarter. TimesSquare Capital Management LLC bought a new position in shares of Insmed in the third quarter valued at approximately $35,322,000. Assenagon Asset Management S.A. boosted its holdings in Insmed by 119.2% during the third quarter. Assenagon Asset Management S.A. now owns 857,360 shares of the biopharmaceutical company’s stock valued at $62,587,000 after acquiring an additional 466,306 shares during the period. Victory Capital Management Inc. boosted its position in shares of Insmed by 209.9% in the third quarter. Victory Capital Management Inc. now owns 455,959 shares of the biopharmaceutical company’s stock valued at $33,285,000 after acquiring an additional 308,819 shares during the period. Finally, Westfield Capital Management Co. LP acquired a new position in shares of Insmed during the third quarter valued at about $18,377,000.

Analyst Ratings Changes

Several brokerages have recently issued reports on INSM. JPMorgan Chase & Co. lifted their price target on Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Friday. Morgan Stanley lifted their target price on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday. HC Wainwright reissued a “buy” rating and issued a $90.00 price target on shares of Insmed in a report on Friday, November 1st. Truist Financial restated a “buy” rating and set a $105.00 price objective (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. Finally, Guggenheim raised their target price on shares of Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a report on Friday. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $85.00.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.